As more and more physicians begin to understand the correlation between mitochondrial dysfunction and diseases such as cancer (and diabetes and dementia, and possibly others), I’m positive that some good things will happen.
One exciting thing is that, with the use of continuous glucose monitors, more and more people are able to see how their food choices impact this process, and then make better food choices.
Another exciting thing is that people are becoming aware of the issue and switching to ketogenic diets, which could reverse diabetes or manage (slow) the progression of cancer.
A new theory of cancer origin was recently introduced. It’s called the mitochondrial-stem cell connection (MSCC) (Martinez, et al., 2024). It builds on two other theories: Dr. Seyfried’s metabolic theory and the cancer stem cell (CSC) theory. I’ll put a link at the bottom if you want to learn more about that. I should mention that Dominic D’Augustino is one of the “et al.”
The exciting thing about this paper recently published on MSCC is that it proposes FIXING the underlying issue rather than focusing on killing cancerous cells.
In the past, most cancer therapies were built on the notion that cancer was genetic… it happened to those who were genetically predisposed to it… and the assumption was that to fight it meant to kill the cells, cut them out, radiate them, etc.
You could say that current cancer treatments are like playing whack-a-mole in an arcade. This new paper suggests we stop wracking the moles and simply unplug the machine from the wall.
Here are some excerpts. I will link the full paper below.
● This connection between CSCs and mitochondria appears to be crucial at all stages of cancer (Martinez, et al., 2024).
● These (standard) therapies do not restore OxPhos and sometimes even alter it (Averbeck & Rodriguez-Lafrasse, 2021; Gorini, et al., 2018). Furthermore, standard therapies only target bulk cells but cannot target cancer stem cells (Lytle, et al., 2018), whereas it is cancer stem cells that have the strongest tumorigenic potential (Adams & Strasser, 2008) and are involved in metastasis.
● Thus, after reviewing the literature on various therapies capable of targeting the MSCC, we selected, based on in vitro and in vivo studies, several orthomolecules, drugs, and additional therapies that have demonstrated an ability to enhance OxPhos, reduce fermentable fuels, and target CSCs and metastasis. Furthermore, when supported by scientific literature, we included case studies of cures using monotherapy in humans. From this combination, we developed a hybrid orthomolecular protocol, which is proposed as a new therapeutic strategy for cancer.
• The degree of malignancy could be directly correlated with significantly lower mitochondria and lower total respiratory capacity in tumor cells (Elliott, et al., 2012; Pedersen, 1978; Seyfried, et al. 2020).
• In order to grow and survive, cancer cells require the primary fuels glucose and glutamine to compensate for OxPhos insufficiency. The respiratory impairment induces overexpression of oncogenes and inactivation of tumor-suppressor genes, which contribute to abnormal energy metabolism in cancer. To date, no evidence has demonstrated the growth of any tumor cells, including CSCs, occurs with the deprivation of fermentable fuels (glucose, pyruvate, or glutamine) (Lee, et al., 2024; Liao, et al., 2017; Holm, et al., 1995; Mathews, et al., 2014; Pastò, et al., 2014).
📖
Read the full paper on MSCC:
https://beatcancerfoundation.org/blog/exciting-news-peer-reviewed-publication-of-groundbreaking-cancer-protocol
Read more about cancer stem cell theory:
https://pmc.ncbi.nlm.nih.gov/articles/PMC6594320/
The Cancer Canary 